newwin
Luciann Nguyen
Settings
← Accounts
biotech

Buzzard Pharmaceuticals

53
Account opportunity
Not established
Relationship
1
Active signals
1
Trials as sponsor

Why this account matters

Buzzard Pharmaceuticals

New trial — Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)

New trialNCT06634875
53/100
Opportunity
Commercial fit11/25
Clinical timing20/20
Biomarker need5/20
Relationship2/10
Signal strength9/10
Account value5/10
Urgency1/5

New phase 2 trial NCT06634875 posted by Buzzard Pharmaceuticals: "Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)". New trial on a phase 2 recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 161 days ago.

ConfidenceHigh · 87%clinical development · translational medicine · clinical operations
Draft outreachReview

NextHold. Score is below the tenant threshold (55). Keep on the watchlist for follow-on signals.

Trials

TrialPhaseTesting language
NCT06634875
Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)
phase 2
—